Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital

Simple item page
dc.contributor.authorAnouchka Seesaghur
dc.contributor.authorP. Egger
dc.contributor.authorJoshua Warden
dc.contributor.authorAli Abbasi
dc.contributor.authorBethany Levick
dc.contributor.authorMajid Riaz
dc.contributor.authorPeter McMahon
dc.contributor.authorMatthew D. Thompson
dc.contributor.authorSue Cheeseman
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:00:32Z
dc.date.available2026-03-22T14:00:32Z
dc.date.issued2023
dc.descriptionCitaciones: 6
dc.description.abstractIn this study identifying BM diagnosis from both structured and unstructured data, a high proportion of patients did not receive a BTA. Unstructured data provide new insights on the real-world use of BTA.
dc.identifier.doi10.1136/bmjopen-2022-069214
dc.identifier.urihttps://doi.org/10.1136/bmjopen-2022-069214
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/44005
dc.language.isoen
dc.publisherBMJ
dc.relation.ispartofBMJ Open
dc.sourceAmgen (United States)
dc.subjectMedicine
dc.subjectProstate cancer
dc.subjectBone metastasis
dc.subjectBreast cancer
dc.subjectHealth records
dc.subjectLung cancer
dc.subjectElectronic health record
dc.subjectOncology
dc.subjectMetastasis
dc.subjectProstate
dc.titleAssessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital
dc.typearticle

Files

Collections

Artículo Científico Publicado